EDITORIAL SECTION

  • STRATEGY

    Smarter Pharma

    Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products

  • EXPERT Talk

    Compliance to Competitive Advantage in Pharma Supply

    Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser

KNOWLEDGE BANK

  • Articles

    Spleen Cytokines Against Inflammatory Bowel Disease

    Over one hundred years ago at the University of Toronto Frederick Banting Charles Best and James Collip extracted protein insulin from the pancreas that saved the lives of millions of diabetics since then It is possible that the proteins extracted from the spleen can also help people with inflammatory bowel disease IBD

    B2B Pharma Magazines: Sponsored Thought Leadership Strategies for Brand Authority

    The pharmaceutical industry has never been short of innovation Every year brings breakthroughs in biologics advanced therapies AIdriven drug discovery manufacturing automation precision medicine and digital health

    Pharmaceutical Business Strategy: Transformation, Regulation, Outsourcing and Growth

    The pharmaceutical industry is standing at an unusual crossroads Patent cliffs are steeper regulators are tougher patients expect more transparency and payers are pushing back harder on price In this environment a strong Pharma Business Strategy is no longer a slide deck exercise for the boardroom its the difference between a company that scales globally and one that quietly fades into irrelevanc...

    B2B Lead Generation Pharma: High-ROI Tactics for European Markets

    The European pharmaceutical industry can be called one of the most complicated and highly regulated markets in the world In the global market where a centralized approval system under the oversight of the European Medicines Agency EMA is required to the reimbursement systems specific to each country in Germany France Italy Spain and the Nordics market entry and market growth needs the accuracy of...

    How AI Could Improve R&D Productivity Across the European Pharma Sector

    Few industries invest in the future as heavily as European pharma According to the regions pharmaceutical industry federation the sector invested an estimated billion in research and development in Europe in making it the most researchintensive industry on the continent Yet boards increasingly confront an uncomfortable asymmetry Spending keeps climbing while the outputs that matter most

    Gene Therapy: Breakthrough Treatments for Rare Diseases

    The idea of gene therapy is radically changing the sphere of medicine with the possibilities to cure the patients with the rare hereditary diseases These diseases which are usually brought about by the alteration of the sequence

TOP ARTICLES

  • 5

    Gene Therapy: Breakthrough Treatments for Rare Diseases

    Kate Williamson

    As a novel healing technique, gene therapy targets core issues in hereditary diseases. This is another approach where damaged genes are altered or removed; this has a ray of hope in diseases like SCID...

press releases Read more...

Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

Biomea Fusion Inc a clinicalstage biopharmaceutical company today announced that it will report results from its Phase I GLP clinical study evaluating BMF an investigational nextgeneration oral smallmolecule GLP receptor agonist on Tuesday

Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs

Bristol Myers Squibb announced positive topline results from the planned interim analysis of the ACTION trial NCT conducted by RayzeBio Inc a Bristol Myers Squibb company The study met the primary endpoint with a statistically significant and clinically meaningful improvement in progressionfree surv...

Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson’s Disease and Exploration of Strategic Options to Maximize Shareholder Value

Jupiter Neurosciences Inc NASDAQ JUNS a clinicalstage biopharmaceutical company developing investigational therapies for neurodegenerative diseases today announced that the first patient has been dosed

First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)

Telix Pharmaceuticals Limited today announces that the first patients in the United States US have been dosed with Pixclara floretyrosine F or FFET its FDAapproved amino acid positron emission

12 - 13

Oct 2026

Pharmaceutics 2026

Village Hotel Changi, Singapor...

12 - 13

Oct 2026

2nd International Conference on Drug Discovery

Village Hotel Changi, Singapor...

21 - 23

Oct 2026

21 - 22

Oct 2026

22 - 23

Oct 2026

PDA Aseptic Symposium 2026

Congress Square Nakanoshima, O...

26 - 28

Oct 2026

ACHEMA Middle East 2026

RICEC, Riyadh, KSA, Saudi Arab...

26 - 28

Oct 2026

World Orphan Drug Congress

RAI, Amsterdam, Netherlands

27 - 28

Oct 2026

Pharma Manufacturing & Automation Convention 2026

Novotel Hyderabad Airport, Ind...

LATEST NEWS Read more...

Catalent and Mantra™ Announce Commercial Supply Agreement for Single-Serve Oral Gel Portfolio

Catalent Inc the leading global contract development and manufacturing organization CDMO dedicated to helping people live better and healthier lives and Mantra a consumer health company developing singleserve over the counter OTC oral gel products for everyday relief

Amphista Therapeutics Announces First Patient Dosed in AMX-883 Phase 1 Clinical Trial for Acute Myeloid Leukemia

Amphista Therapeutics Limited a leader in the discovery and development of noncereblon VHL targeted protein degradation TPD medicines today announced dosing of the first patient in a Phase trial for its lead candidate AMX Initiated following authorization from the US Food and Drug Administration i...

Sensible Biotechnologies Secures $47 Million to Advance Cell-Based mRNA Platform

Sensible Biotechnologies has secured million in financing to advance and scale its platform for producing naturally modified messenger RNA mRNA medicines The funding includes a Series A round

PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics

PacBio and TychoBio have entered into a collaboration to generate fulllength RNA data for training artificial intelligence AI models designed to support RNA therapy development for rare diseases

Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialise EXPAREL® in the European Union and UK

Pacira BioSciences has entered into a strategic agreement with Molteni Farmaceutici to expand access to EXPAREL bupivacaine liposome injectable suspension for postsurgical pain management across selected European markets

ORIC Pharmaceuticals and Cancer Research UK Partner to Advance CIP2A-Targeted Cancer Therapy

ORIC Pharmaceuticals has entered into an agreement with Cancer Research UK to advance ORIC a potential firstinclass therapy targeting Cancerous Inhibitor of PPA CIPA into clinical development